TickerFacts.

Tevogen Inc. (TVGN): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$12.39M
Year ended 2025-12-31
2023-12-31: -$8.30M2025-12-31: -$12.39M-$12.39M
2023-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$12.39Mn/a2026-03-31, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31-$8.30Mn/a2025-04-02, From 2023-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Tevogen Inc. (TVGN)2025-12-31-$12.39Mn/a
BioCardia, Inc. (BCDA)2025-12-31-$7.44Mn/m
AIM ImmunoTech Inc. (AIM)2024-12-31-$14.91Mn/a
Exozymes Inc. (EXOZ)2025-12-31-$6.67Mn/m
Silexion Therapeutics Corp (SLXN)2025-12-31-$10.83Mn/m
VivoSim Labs, Inc. (VIVS)2026-03-31-$10.83Mn/m
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31-$6.05Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$741.0Kn/a
Entera Bio Ltd. (ENTX)2025-12-31-$7.48Mn/m

Compare TVGN, BCDA, AIM, EXOZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗